18:49 , Jul 13, 2018 |  BioCentury  |  Finance

Curating Abingworth

With a narrower set of investment strategies and a diversified LP base for its latest fund, Abingworth is seeking double digit returns from the $315 million Bioventures VII. Abingworth’s Kurt von Emster told BioCentury the...
22:26 , Jan 11, 2018 |  BC Extra  |  Company News

Pfizer's Barrett named CEO of Novartis Oncology

Novartis AG (NYSE:NVS; SIX:NOVN) hired Elizabeth Barrett as CEO of Novartis Oncology, effective Feb. 1. She succeeds Bruno Strigini, who is retiring for personal reasons (see BioCentury Extra, Dec. 15, 2017). Barrett is global president and...
00:38 , Jan 6, 2018 |  BioCentury  |  Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to a...
04:21 , Dec 9, 2017 |  BioCentury  |  Product Development

Multimodal meeting

This year’s clinical abstracts at the American Society of Hematology meeting hint at how newer treatment modalities -- cell therapies in cancer and gene therapies in hematology -- will branch out into new indications and...
23:52 , Oct 6, 2017 |  BioCentury  |  Finance

Bargain shopping

With all companies valued over $1 billion increasing a median of at least 16.8% in 1H17, investors went bargain shopping in the $500-$999 million tier in 3Q17. The group outperformed all other market cap bands,...
19:49 , Aug 18, 2017 |  BC Week In Review  |  Clinical News

FDA approves Pfizer's Besponsa to treat ALL

FDA approved a BLA from Pfizer Inc. (NYSE:PFE) for Besponsa inotuzumab ozogamicin (CMC-544, PF-5208773) to treat adults with relapsed or refractory B cell precursor acute lymphoblastic leukemia. Besponsa’s label includes a boxed warning for hepatotoxicity, including...
21:56 , Aug 17, 2017 |  BC Extra  |  Company News

FDA approves Pfizer's Besponsa for ALL

FDA approved a BLA from Pfizer Inc. (NYSE:PFE) for Besponsa inotuzumab ozogamicin to treat adults with relapsed or refractory B cell precursor acute lymphoblastic leukemia. Besponsa’s label includes a boxed warning for hepatotoxicity, including hepatic veno-occlusive...
00:20 , Jul 8, 2017 |  BioCentury  |  Finance

A clinical quarter

Buysiders will find themselves digesting at least 23 Phase III data readouts in the next quarter, two of which could provide clarity on increasingly competitive markets in lung cancer and hemophilia. The third quarter is...
23:40 , Jul 7, 2017 |  BioCentury  |  Finance

Onward and upward

The top three market cap tiers continued to outperform smaller caps in 2Q17, led by companies valued between $1 billion and $9.9 billion. Companies valued below $1 billion failed to carry over their momentum from...
20:13 , Jul 7, 2017 |  BC Week In Review  |  Clinical News

EC approves Pfizer’s Besponsa for ALL

Pfizer Inc. (NYSE:PFE) said the European Commission approved an MAA for Besponsa inotuzumab ozogamicin (CMC-544, PF-5208773) as monotherapy to treat relapsed or refractory CD22-positive, B cell precursor acute lymphoblastic leukemia (ALL). In patients with Philadelphia...